title: [Botulinum toxin in the treatment of adult spasticity. An interdisciplinary German 10-point consensus 2010].
abstract: Spasticity is one of the major causes of functional impairment in adults with lesions of the central nervous system. For instance, approximately 30% of post-stroke patients suffer from different degrees of spasticity with possible consecutive impairments. Numerous studies or meta-analyses showed that local injections of botulinum toxin in spastic muscles lead to dose-dependent reduction in muscle tone and improvement of passive movements (e. g. facilitated care), especially following repeated injections.However, country-specific regulations and patient-remote administration in German health care often do not allow adequate provision of this therapy. Thus, the present consensus statement based on the EBM analyses of the published international literature tries to highlight recent advances and the standard in the field of local spasticity treatment, aiming to facilitate communication between the decision makers and German reimbursement institutions in health care. Prior to initiation of BoNT-A injections, patient-oriented goals should be identified in a multiprofessional context to assure realistic goals for this specific treatment and patient expectations. In Germany for the treatment of focal spasticity following stroke three products have been approved: Botox® (Pharm Allergan, Ettlingen), Dysport® (Ipsen Pharma, Ettlingen) and Xeomin® (Merz Pharma, Frankfurt/Main). For all preparations safety has been repeatedly shown. Functional improvements have also been illustrated for selected patients concerning hand/arm function and gait. The dose per muscle and the selection of muscles to be injected have to be individualized according to the patient's symptoms and should be accompanied by modern neurorehabilitative therapies such as redression or repetitive activation of the injected and antagonistic muscles.
authors.affiliation: Kliniken Beelitz GmbH, Paracelsusring 6 A, 14547, Beelitz-Heilstätten. wissel@rehaklinik-beelitz.de
authors.forename: J
authors.initials: J
authors.lastname: Wissel
authors.forename: M
authors.initials: M
authors.lastname: auf dem Brinke
authors.forename: M
authors.initials: M
authors.lastname: Hecht
authors.forename: C
authors.initials: C
authors.lastname: Herrmann
authors.forename: M
authors.initials: M
authors.lastname: Huber
authors.forename: S
authors.initials: S
authors.lastname: Mehnert
authors.forename: I
authors.initials: I
authors.lastname: Reuter
authors.forename: A
authors.initials: A
authors.lastname: Schramm
authors.forename: A
authors.initials: A
authors.lastname: Stenner
authors.forename: C
authors.initials: C
authors.lastname: van der Ven
authors.forename: M
authors.initials: M
authors.lastname: Winterholler
authors.forename: A
authors.initials: A
authors.lastname: Kupsch
mesh_terms: D000328:Adult; D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use*; D005858:Germany; D006801:Humans; D009128:Muscle Spasticity / Q000188:drug therapy*; D009462:Neurology / Q000592:standards*; D017410:Practice Guidelines as Topic
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins